Related Experiment Videos
Immunodetection and characterisation of soluble CD105-TGFbeta complexes
C G Li1, P B Wilson, C Bernabeu
1Department of Pathological Sciences, Medical School, The University, Manchester, UK.
Journal of Immunological Methods
|November 18, 1998
Summary
A new assay quantifies soluble CD105-TGFbeta1 complexes, revealing elevated levels in breast cancer patients. This method offers potential for diagnosing angiogenic diseases.
Area of Science:
- Biochemistry
- Immunology
- Oncology
Background:
- CD105 (endoglin) is a transforming growth factor beta (TGFbeta) receptor.
- Existing assays measure soluble TGFbeta and CD105 separately, not their complexes.
- Quantifying CD105-TGFbeta complexes is crucial for understanding their biological roles.
Purpose of the Study:
- To develop and validate an assay for quantifying soluble CD105-TGFbeta1 complexes.
- To characterize the molecular forms of these complexes in plasma.
- To assess the clinical utility of the assay in breast cancer patients.
Main Methods:
- Indirect enzyme-linked immunosorbent assay (ELISA) using a specific anti-CD105 antibody (Mab E9) for capture.
- Detection of TGFbeta1 using a chicken antibody, followed by an anti-species antibody conjugated to horseradish peroxidase (HRP).
- Immunoprecipitation and immunoblotting to characterize complex molecular weights and properties.
Main Results:
- A sensitive and reproducible ELISA was established for soluble CD105-TGFbeta1 complexes.
- Plasma levels were significantly elevated in breast cancer patients compared to healthy controls (p < 0.001).
- Three distinct molecular forms of the complex (>200, 195, and 125 kDa) were identified, likely representing oligomers, dimers, and degraded forms.
Conclusions:
- The developed assay reliably quantifies soluble CD105-TGFbeta1 complexes.
- Elevated levels in breast cancer suggest potential as a diagnostic or prognostic biomarker.
- The assay may have clinical applications in various angiogenic diseases beyond cancer.